What is Kronos Bio Debt-to-Equity?
Kronos Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.89 Mil. Kronos Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $25.38 Mil. Kronos Bio's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $159.08 Mil.
Kronos Bio's debt to equity for the quarter that ended in Dec. 2023 was 0.18.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Kronos Bio's Debt-to-Equity or its related term are showing as below:
KRON'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.11 Med: 0.08 Max: 0.18
Current: 0.18
During the past 6 years, the highest Debt-to-Equity Ratio of Kronos Bio was 0.18. The lowest was -0.11. And the median was 0.08.
Kronos Bio Debt-to-Equity Historical Data
The historical data trend for Kronos Bio's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kronos Bio Debt-to-Equity Chart
|
Kronos Bio Annual Data
|
|
Trend |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
-0.02 |
0.07 |
0.10 |
0.13 |
0.18 |
|
Kronos Bio Quarterly Data
|
|
Dec18 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.13 |
0.14 |
0.15 |
0.17 |
0.18 |
Competitive Comparison of Kronos Bio's Debt-to-Equity
For the Biotechnology subindustry, Kronos Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kronos Bio's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kronos Bio's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Kronos Bio's Debt-to-Equity falls into.
Kronos Bio Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Kronos Bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Kronos Bio's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kronos Bio (Kronos Bio) Business Description
Traded in Other Exchanges
N/A
Address
1300 So. El Camino Real, Suite 300, San Mateo, CA, USA, 94402
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
Executives
| Jorge Dimartino |
officer: Chief Medical Officer & VP |
C/O KRONOS BIO, INC., 1300 S, SAN MATEO CA 94402 |
| Christopher Dinsmore |
officer: Chief Scientific Officer |
C/O KRONOS BIO, INC., 1300 EL CAMINO REAL, STE. 300, SAN MATEO CA 94402 |
| Barbara Kosacz |
officer: COO & General Counsel |
3175 HANOVER STREET, PALO ALTO CA 94304 |
| Norbert W Bischofberger |
director, 10 percent owner, officer: President & CEO |
333 LAKESIDE DR, C/O GILEAD SCIENCES, INC., FOSTER CITY CA 94404 |
| Sandra A. Gardiner |
officer: Interim CFO |
CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
| Yasir B. Al-wakeel |
officer: Chief Financial Officer |
MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
| Roger D Dansey |
director |
21823 30TH DRIVE SE, BOTHELL WA 98021 |
| Katherine V Stultz |
director |
C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080 |
| Backer Marianne De |
director |
177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105 |
| Roshawn A. Blunt |
director |
11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130 |
| Jakob Loven |
director |
C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511 |
| Taiyin Yang |
director |
2631 HANOVER STREET, PALO ALTO CA 94304 |
| Otello Stampacchia |
director, 10 percent owner |
888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
| John C Martin |
director |
333 LAKESIDE DRIVE, FOSTER CITY X1 94404 |
| Elena Ridloff |
director |
C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Kronos Bio (Kronos Bio) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KRON has been successfully added to your